

Keith A. Dookeran MBBS FRCS(Ed) MD MBA PhD

Current Position: Visiting Assistant Professor of Epidemiology

Business Address: University of Wisconsin-Milwaukee, Joseph J. Zilber School of Public Health, Rm 390

Email: dookeran@uwm.edu

Web links: <https://www.linkedin.com/in/keith-dookeran-md-phd-21a5476/>; <https://www.ncbi.nlm.nih.gov/myncbi/keith.dookeran.1/cv/108015/>

EDUCATION:

- Bachelor of Medicine/Bachelor of Surgery (MBBS); May 1985; Univ. West Indies, School of Medicine, Mona, Jamaica; Medicine/Surgery
- Fellowship Diploma in General Surgery (FRCS(Ed)); January 1990; Royal College of Surgeons of Edinburgh, UK; General Surgery
- Doctor of Medicine (MD); December 2007; Univ. Leicester, UK; Translational Surgical Oncology
- Master of Business Administration (MBA); June 2009; Univ. Chicago, Booth School of Business; concentrations in Health Administration & Policy, and Managerial & Organizational Behavior
- Doctor of Philosophy in Public Health (PhD); August 2016; Univ. Illinois at Chicago, School of Public Health; Cancer, Molecular and Genetic Epidemiology

MEDICAL TRAINING:

- 1985-1987; Univ. West Indies Medical School, Port of Spain, Trinidad; Residency in General Surgery
- 1988-1991; University Hospitals of Leicester NHS Trust, Leicester, UK; Residency in General Surgery
- 1992-1994; University Hospitals of Leicester NHS Trust, Leicester, UK; Research Fellowship in Breast Oncology
- 1994-1997; Division of Surgical Oncology, Univ. Pittsburgh, PA; Fellowship in Surgical Oncology

LICENSURE/CERTIFICATION (all current):

- 1990; Diploma, Fellowship of the Royal College of Surgeons, Edinburgh, UK; #9074
- 1993; Educational Commission for Foreign Medical Graduates; #0-497-339-2
- 1988; General Medical Council, UK; #3384899
- 1995; State of Pennsylvania, Bureau of Professional Affairs; MD-055995-L
- 1997; US Drug Enforcement Agency; BD-4969614
- 1999; State of Illinois, Department of Professional Regulation; #036-101482
- 1999; State of Illinois, Department of Professional Regulation, controlled substance license; #336-062310

ACADEMIC APPOINTMENTS:

- 1998-2000; Assistant Prof. of Surgery, Division of Surgical Oncology; Univ. Pittsburgh, PA
- 2004-2006; Assistant Prof., Department of Surgical Oncology; Univ. Illinois at Chicago, IL
- 2016-present; Assistant Prof. Epidemiology, University of Wisconsin-Milwaukee, Joseph J. Zilber School of Public Health

HOSPITAL APPOINTMENTS:

- 1997-1999; Attending Surgeon; UPMC Mercy, PA
- 1999-2006; Attending Surgeon; Cook County Hospital, IL
- 2004-2006; Attending Surgeon; UIC Medical Center, IL

OTHER EMPLOYMENT:

- 2006-present; Chairman/ Principal Consultant; CFMUP Consulting (Cancer Foundation for Minority and Underserved Populations, IL)
- 2009; Independent Consultant (Oncology CRO Development); Moffitt Cancer Center, Tampa Bay, FL
- 2013-2016; Cancer Epidemiology Research Fellow, Div. Epidemiology and Biostatistics, School of Public Health, Univ. Illinois at Chicago

OTHER CONSULTING:

- 2014; Independent Consultant; Health Engine, Chicago, IL (*Pro Bono*)
- 2015; Independent Consultant; Thermatome Corporation, IL (*Pro Bono*)

HONORS AND AWARDS:

- 2009-present; Minorities in Cancer Research; Database of Exceptional Minority Scientists

PROFESSIONAL ORGANIZATION (memberships):

- The Royal College of Surgeons, Edinburgh (RCS Ed), UK
- The Association of Surgeons of Great Britain & Ireland (ASBGI), UK
- The British Medical Association (BMA), UK
- The British Association of Surgical Oncology (BASO), UK
- The European Society of Surgical Oncology (ESSO), UK
- The British Oncological Association (BOA), UK
- The Surgical Research Society (SRS), UK

- The Society for Biologic Therapy (SBT)
- The American Association for Cancer Research (AACR)
- The American Society of Clinical Oncology (ASCO)
- The Society of Academic and Research Surgery (SARS), UK
- The American Society of Breast Disease (ASBD)
- The Society of Surgical Oncology (SSO)
- The Association of Breast Surgery at BASO, UK
- The Illinois Medical Oncology Society (IMOS)
- The American Society of Breast Surgeons
- The Int. Soc. of Cancer Risk Assessment & Management (ISC-RAM)
- The Society for Epidemiologic Research (SER)

PROFESSIONAL ACTIVITIES:

INSTITUTIONAL SERVICE:

- 1997-1998; Director of Clinical Oncology Trials & Research; UPMC Mercy, PA
- 1997-1998; Director Surgical Research; UPMC Mercy, PA
- 1999-2006; Associate Chair of Surgery; Cook County Hospital
- 1999-2006; Associate Research Integrity Officer; Cook County Hospital
- 2002-2006; Co-Principal Investigator MBCCOP; Cook County Hospital
- 2011-2016; UIC SPH; Executive Committee
- 2013-2016; UIC SPH; Leadership Council
- 2016-2018; Zilber SPH; Faculty Committee on Research and Seminars
- 2016-2018; Zilber SPH; Epidemiology Track Faculty Admissions Committee
- 2017-2018; UWM Academic Staff Senate

TEACHING:

- 1997-1999; Associate Director Joint Surgical Oncology Fellowship Program; UPMC Mercy, PA
- 1998-1999; Associate Director General Surgery Residency Program; UPMC Mercy, PA
- 2012-2015; Teaching Assistant; Division of Epidemiology and Biostatistics, UIC SPH
- 2012-2015; Leader/Co-Chair Graduate Level Journal Club; Division of Epidemiology and Biostatistics, UIC SPH
- 2016-2017; PH768 Cancer Epidemiology, UWM Zilber SPH
- 2016-2017; PH804 Advanced Epidemiology Methods, UWM Zilber SPH
- 2016-2018; PH101 Introduction to Public Health, UWM Zilber SPH
- 2017-2018; PH904 Survey of Analytic Methods for Epidemiology, UWM Zilber SPH

EXTRAMURAL MEMBERSHIPS:

- American Association for Cancer Research (AACR):
 - a. 2009-2010; Minorities in Cancer Research; Communications Committee
 - b. 2009-2010; Minorities in Cancer Research; Professional Advancement Committee
 - c. 2010-2011; Minorities in Cancer Research; Minority Scholar Awards Committee
 - d. 2011-2012; Minorities in Cancer Research; Communications Committee
 - e. 2012-2013; Minorities in Cancer Research; Communications Committee
 - f. 2014-2015; Minorities in Cancer Research; Minority Scholar Awards Committee
- American Society of Breast Disease (ASBD):
 - a. 2004-2007; Outreach and Special Populations Committee
- National Cancer Institute (NCI) Committees:
 - a. 2004-2006; MBCCOP Principal Investigators Committee
 - b. 2007; Estrogen Receptor Negative Breast-Cancer-Workshop Committee
- NCI Cooperative Group Committees:
 - a. 2003; NSABP Breast Technology Assessment Group
 - b. 2007; ECOG Auditor

EDITORIAL RESPONSIBILITIES:

- 2000-2016; Editorial Board; Breast Diseases: A Year Book Quarterly

PEER REVIEW RESPONSIBILITIES:

- Ad Hoc Journal Reviewer:
 - a. Cancer
 - b. Cancer Epidemiology, Biomarkers and Prevention
 - c. Annals of Surgical Oncology

- d. European Journal of Surgical Oncology
- e. Radiation Oncology
- f. Breast Cancer: Targets and Therapy
- g. BMC Cancer
- h. Plos One
- i. Breast Cancer Research and Treatment

GRANT AWARDS (COMPLETED):

- 2013/08/31-2016/09/01
 - KG111385, Komen Foundation
 - Rauscher, Garth (PI)
 - UIC Komen Cancer Epidemiology and Disparities Fellowship*
 - The program goal was to train a cadre of researchers to conduct breast cancer disparities research most relevant to public health goals.
 - Role: Fellow
 - 2010/06/30-2012/05/31
 - JDOM2921, NIHLRP
 - Dookeran, Keith (PI)
 - Race based differences in tumor biology among low SES women with breast cancer*
 - The program goal was to study disaggregation of the effects of race, tumor biology, and socioeconomic status (SES), on survival and prognosis in minority-underserved women with breast cancer.
 - Role: Principal Investigator
 - 2002/06/01-2008/05/31
 - Avon Foundation
 - Dookeran, Keith (PI)
 - Minority-underserved clinical research support program at Cook County Hospital*
 - The program goals included: to expand efforts to bring state-of-the-art, quality breast oncology care to minority-underserved populations; to support continued participation in NCI-supported clinical trials; and increase the capacity of the patient navigator staff.
 - Role: Principal Investigator
 - 2002/06/01-2007/05/31
 - U10CA095867, NCI
 - Zaren, Howard (PI)
 - Cook County Hospital MBCCOP*
 - The program goal was development, growth and expansion of the NCI-supported Minority-Based Community Clinical Oncology Program (MBCCOP) at a public institution that largely treats the indigent and poor, Cook County Hospital, in Chicago, IL.
 - Role: Co-Principal Investigator
 - 2000/06/01-2004/05/31
 - Aventis Pharmaceuticals
 - Dookeran, Keith (PI)
 - Minority-underserved clinical oncology research support and development program at Cook County Hospital*
 - The program goals included: to support development of an oncology clinical trials unit; to support continued participation in NCI-supported and industry clinical trials; to expand efforts to bring state-of-the-art, quality oncology research, technology and care to minority-underserved populations; and increase the capacity of research patient navigator staff.
 - Role: Principal Investigator

INVITED LECTURES AND PRESENTATIONS:

- November 1991 pS2 immunohistochemical staining in breast cancer: positive correlation with endocrine response. The British Association of Surgical Oncology, 43rd Scientific Meeting, at the University College and Middlesex School of Medicine, London, UK.
- January 1992 Surgical Quality Assurance for screening mammography in Leicester: Audit of early results. Meeting held at the Trent Regional Health Authority, Nottingham City Hospital, Nottingham, UK.
- January 1992 The significance of pS2 immunoreactivity in primary breast carcinomas. Pathological society of Great Britain and Ireland, 164th Scientific Meeting, at The Hammersmith Hospital, London, UK.
- February 1992 The axilla: staging and treatment in Breast Cancer. Symposium: Update on the Management of Breast Cancer. Meeting held at the Post Graduate Medical Center, University of Leicester, at the Leicester Royal Infirmary, Leicester, UK.
- February 1992 Prediction of Endocrine Response in Breast Cancer: Evaluation of New Endocrine Markers. The Leicester Postgraduate Research Prize. Meeting held at the Post Graduate Medical Center, University of Leicester, at the Leicester Royal Infirmary, Leicester, UK.
- July 1992 The significance of pS2 luminal immunoreactivity in breast cancer. The 76th meeting of The Surgical Research Society, at the University of Edinburgh, Edinburgh, UK.
- July 1992 Evaluation of pS2 expression in primary breast tumors: prediction of response to endocrine therapy. The 7th Scientific Meeting of The British Oncological Association in association with The Nordic Cancer Societies, at the University of Kent, Canterbury, UK.

- July 1992 pS2 immunoreactivity in primary breast tumors: the significance of luminal & cytoplasmic staining. The British Association of Surgical Oncology, 44th Scientific Meeting, at The University of South Manchester, Manchester, UK.
- September 1992 pS2 expression in primary breast tumors: prediction of response to endocrine therapy. The 2nd Nottingham International Breast Cancer Meeting, at the City Hospital, Nottingham, UK.
- September 1992 The value of pS2 expression in predicting response to endocrine therapy in moderately and poorly differentiated primary breast tumors. The Association of Surgeons of Great Britain and Ireland, Trinity 400 Meeting, at the University of Dublin, Ireland.
- October 1992 Adjuvant treatment of Breast Cancer: New Insights after the World Overview. Symposium: Current Breast Cancer Management. Meeting held at the Breast Cancer Research Unit, University of Leicester, at the Glenfield General Hospital, Leicester, UK.
- October 1992 Comparison of pS2 and Cathepsin D expression in breast carcinomas. The British Breast Group, London, UK.
- November 1992 Cathepsin D & pS2 expression in breast tumors: relationship with response to endocrine therapy. The British Association of Surgical Oncology, 45th Scientific Meeting, at the Charing Cross and Westminster Medical School, London, UK.
- January 1993 Comparison of pS2 and Cathepsin D expression in breast carcinomas. Pathological society of Great Britain and Ireland, 166th Scientific Meeting, at The St. Mary's Hospital Medical School, London, UK.
- March 1995 Tumour targeted delivery of sustained release, high dose 9-Aminocamptothecin. The 86th annual meeting of the American Association of Cancer Research, in Toronto, Ontario, Canada.
- May 1995 Ethiodol: A novel vehicle for drug and cytokine delivery in the treatment of cancer. The 1995 UPMC Oakland Scientific meeting, at the Holiday Inn University Center, Pittsburgh, PA.
- October 1995 Eradication of hepatic metastases with intra-hepatic arterial infusion of sustained release 9-aminocamptothecin. Surgical Grand Rounds, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
- October 1995 Eradication of hepatic metastases with intra-hepatic arterial infusion of sustained release 9-aminocamptothecin. The 81st Clinical Congress of the American College of Surgeons, New Orleans, LA.
- November 1995 Effective therapy of hepatic metastases with intra-hepatic arterial infusion of sustained release interleukin-2. The 10th annual scientific meeting of the Society for Biologic Therapy in Williamsburg, VA.
- March 1996 Antitumor activity of intrahepatic arterial 9-AC and ethiodol exceeds that of systemic 9-AC. The 49th annual cancer symposium of the Society of Surgical Oncology in Atlanta, GA.
- April 1996 Low dose systemic interleukin-2 regimens in patients with significant co-morbid illness. The American Association of Cancer Research 1996 annual scientific meeting in Washington, DC.
- November 1996 Effective antitumor activity of Interferon-alfa plus ethiodol in animal models. The 38th annual meeting of the American Association of Academic Surgeons November 13-16, 1996, Chicago, IL.
- March 1997 Effective gene therapy of murine breast cancer liver metastases with IL-12. The 50th annual cancer symposium of the Society of Surgical Oncology in Chicago, IL.
- April 1997 Combined filtered 99m Tc sulfur colloid and isosulfan blue dye in localization and identification of sentinel lymph nodes and their ability to predict the presence or absence of metastases in the axillary lymph nodes. American College of Radiology annual meeting, April 18 - 21, 1998, Washington, DC.
- March 1997 Locoregional therapy of cancer with Nitric Oxide donors delivered in Ethiodol. The 50th annual cancer symposium of the Society of Surgical Oncology in Chicago, IL.
- April 1997 Antitumor activity of Taxol in Ethiodol. The 88th annual meeting of the American Association of Cancer Research, San Diego, CA.
- April 1997 Recombinant human TNF alpha produces neutrophil nadir in peripheral blood and hemorrhagic necrosis in syngenic murine breast carcinoma model. The 88th annual meeting of the American Association of Cancer Research in San Diego, CA.
- May 1997 Selective lymphadenectomy in women with primary breast cancer. Oncology Grand Rounds, Mercy Hospital of Pittsburgh, PA.
- November 1997 Ductal carcinoma in situ of the breast: Management concepts in evolution. Surgical Grand Rounds, Department of Surgery, the Mercy Hospital of Pittsburgh, PA.
- January 1998 Therapeutic options for ductal carcinoma in situ of the breast. Oncology Grand Rounds, the Mercy Hospital of Pittsburgh, PA.
- January 1998 Advanced Breast Biopsy Instrumentation (ABBI) surgical preceptorship. Forbes Regional Hospital, Pittsburgh, PA.
- February 1998 Adjuvant chemotherapy for breast cancer administered by surgical or medical oncologists: No difference in therapy. Annual Scientific meeting of the Southeastern Surgical Congress, Atlanta, GA.
- March 1998 Effective regional therapy of cancer with sustained-release, nitric oxide-donor, Nitroprusside in Ethiodol. The 51st Cancer Symposium of the Society of Surgical Oncology, San Diego, CA.
- March 1998 Intraoperative Lymphatic Mapping for Breast Cancer. Surgical Grand Rounds at Meadville/Hamot Med. Centers, Meadville, PA.
- March 1998 Relationship of glucose transporter 1 and p53 expression in human breast cancer. The 89th annual meeting of the American Association for Cancer Research, New Orleans, LA.
- April 1998 Combined filtered technetium-99 sulfur colloid and Isosulfan Blue dye in localization and identification of Sentinel lymph nodes and their ability to predict the presence or absence of metastases in axillary lymph nodes. The 28th Annual National Conference on Breast Cancer of the American College of Radiology, Washington, DC.
- April 1998 Adjuvant chemotherapy for breast cancer administered by Surgical or Medical Oncologist: No difference in therapy. Mercy Research Day 1998 Scientific oral presentations on breast cancer, The Mercy Hospital of Pittsburgh, Pittsburgh, PA.
- April 1998 Relationship of glucose transporter 1 and p53 over-expression in human breast cancer. Mercy Research Day 1998 Scientific oral presentations on breast cancer, the Mercy Hospital of Pittsburgh, Pittsburgh, PA.
- April 1998 Breast cancer and DCIS: Staging and treatment differences. Pennsylvania Association of Cancer Registrars Annual Meeting, the Mercy Hospital of Pittsburgh, Pittsburgh, PA.

- April 1998 Prospective evaluation of the Advanced Breast Biopsy (ABBI) System as a method for stereotactic breast biopsy of mammographic non-palpable abnormalities. The West Virginia Chapter of the American College of Surgeons Spring 1998 Meeting, Greenbrier, White Sulphur Springs, WV.
- June 1998 New surgical methods for minimally invasive breast biopsy. The Southwestern Pennsylvania Chapter of the American College of Surgeons 44th Annual Meeting, Pittsburgh, PA.
- June 1998 Sentinel Lymph Node Biopsy for breast cancer. The Southwestern Pennsylvania Chapter of the American College of Surgeons 44th Annual Meeting, Pittsburgh, PA.
- June 1998 New Surgical Modalities in the Diagnosis and Treatment of Breast Cancer. The Alma Carlson Oniboni Oncology Nursing Conference: Women & Cancer, The Mercy Hospital of Pittsburgh, Pittsburgh, PA.
- June 1998 The role of the ABBI biopsy in patients with mammographic abnormalities. The 25th Annual Summer Meeting of the British Association of Surgical Oncology, Liverpool Football Club, UK.
- June 1998 Parallel expression of glucose transporter 1 and p53 on primary breast cancer. The 25th Annual Summer Meeting of the British Association of Surgical Oncology, Liverpool Football Club, UK.
- October 1998 Highlights of the Mercy Hospital Breast Cancer Program. The 4th Annual Bernard Fisher Lectureship, held at the Westin William Penn hotel, Pittsburgh, PA.
- November 1998 Prospective evaluation of the Advanced Breast Biopsy (ABBI) System as a method for stereotactic breast surgery of mammographic non-palpable abnormalities. The 84th Scientific Assembly and Annual Meeting of the Radiological Soc. of North America, Chicago, IL.
- November 1998 The efficacy of combined dye approach in identifying sentinel nodes in patients with breast cancer. The 84th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL.
- November 1998 Relationship of Glucose Transporter 1 and cerb-B2 in primary human breast cancer. The 32nd Annual Meeting of the Association for Academic Surgery, Seattle, WA.
- January 1999 ABBI results and out-takes. The University of South Florida & Moffitt Cancer Center radioguided surgery & minimally invasive breast biopsy course, Moffitt Cancer Center, Tampa, FL.
- January 1999 Selection of large and small core breast biopsy. The University of South Florida & Moffitt Cancer Center radioguided surgery & minimally invasive breast biopsy course, Moffitt Cancer Center, Tampa, FL.
- February 1999 Analysis of eligibility criteria for ABBI procedures in patients with nonpalpable mammographic abnormalities. The 1999 Annual Scientific meeting of the Southeastern Surgical Congress, Tampa, FL.
- February 1999 Relationship of Glucose Transporter 1 and Cathepsin-D in human primary breast cancer. The 1999 Annual Scientific meeting of the Southeastern Surgical Congress, Tampa, FL.
- February 1999 p53 and Glucose Transporter 1 expression in chronic active gastritis associated with Helicobacter Pylori infection. The 1999 Annual Scientific meeting of the Southeastern Surgical Congress, Tampa, FL.
- February 1999 ABBI results and out-takes. The University of South Florida & Moffitt Cancer Center radioguided surgery & minimally invasive breast biopsy course, Moffitt Cancer Center, Tampa, FL.
- February 1999 Selection of large and small core breast biopsy. The University of South Florida & Moffitt Cancer Center radioguided surgery & minimally invasive breast biopsy course, Moffitt Cancer Center, Tampa, FL.
- April 1999 Correlation of touch preparation cytology, conventional histology and cytokeratin immunohistochemistry for sentinel lymph nodes in patients with breast cancer. The 90th annual meeting of the American Association for Cancer Research, Philadelphia, PA.
- May 1999 Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. The 35th annual meeting of the American Society of Clinical Oncology, Atlanta, GA
- June 1999 The efficacy of the combined dye approach in identifying sentinel lymph nodes in patients with breast cancer. Oncology Grand Round, Reynolds Memorial Hospital, Wheeling, WV.
- April 2000 Mechanisms of antitumor activity for sustained-release nitric-oxide donor, Nitroprusside in Ethiodol. The 91th annual meeting of the American Association for Cancer Research, San Francisco, CA.
- May 2000 Ductal carcinoma in situ of the breast: Current management. Joint Rush Presbyterian St. Luke's Medical Center and CCH Hematology/ Oncology fellowship lecture series, Chicago, IL.
- July 2000 Clinical diagnosis of breast disease. CCH Breast and Cervical Cancer Screening Educational Conference, Chicago, IL.
- July 2000 A practical approach to common breast problems. CCH Breast/Cervical Cancer Screening Educational Conference, Chicago, IL.
- March 2001 Prognostic Differences for African-American and Other Medically-Underserved Patients with Breast Cancer. The 92nd annual meeting of the American Association for Cancer Research, New Orleans, LA.
- March 2001 The Surgical Approach for Diagnosis and Treatment of Mammographically Detected Breast Disease. Radiology Grand Rounds, University of the West Indies School of Medicine St Augustine Campus, Mt. Hope, Trinidad. W.I.
- March 2001 Current "State of the Art" Management of Breast Cancer. Radiology Grand Rounds, University of the West Indies School of Medicine St Augustine Campus, Mt. Hope, Trinidad. W.I.
- May 2001 Clinical trials and tribulations at CCH: implementation of NSABP breast cancer studies. Spring Meeting of the Illinois Surgical Society at CCH, Chicago, IL.
- January 2002 The enigma of poorer outcomes for minority patients with breast cancer. Department of Family Practice Grand Rounds, CCH, Chicago, IL.
- January 2002 An introduction to breast imaging. Department of Family Practice Grand Rounds, CCH, Chicago, IL.
- February 2002 Factors influencing postmastectomy breast reconstruction among minority-underserved patients. The 7th Annual Multidisciplinary Symposium on Breast Disease, Amelia Island, FL.

- April 2002 Comparison of prognostic factors for minority-underserved patients with breast cancer. The 93rd annual meeting of the American Association for Cancer Research, San Francisco, CA.
- April 2002 Outcomes for breast cancer screening & early detection in minority-underserved women. The 93rd annual meeting of the American Association for Cancer Research, San Francisco, CA.
- April 2002 Analysis of results for breast cancer screening & early detection in minority-underserved American women. The 11th Congress of the European Society of Surgical Oncology, Lille, France.
- April 2002 A comparison of prognostic factors for minority-underserved American patients with breast cancer The 11th Congress of the European Society of Surgical Oncology, Lille, France.
- April 2002 A Surgical Perspective of Breast Cancer Screening & Early-Detection in Minority-Underserved Women. Chicago Board of Health, Grand Rounds, Chicago, IL.
- July 2002 Black women with breast cancer are more likely to be ER-beta positive. British Cancer Research Meeting 2002, Glasgow, Scotland.
- July 2002 Her2/Neu overexpression in Black women with breast cancer is not associated with negative ER status or higher stage disease. British Cancer Research Meeting 2002, Glasgow, Scotland.
- October 2002 Analysis of results for breast cancer screening & early detection in minority-underserved American women. The Fourth Annual Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IL.
- December 2002 Fine needle aspirate biopsies of breast lesions are more commonly unsatisfactory and inaccurate when performed by non-surgeons. The 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- May 2003 Recruitment & Retention of Minority-Underserved Participants to the Star/P2 study is Difficult. The 2003 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
- July 2003 Minority-Underserved Women Treated for Breast Cancer Are at Increased Risk for Poor Mental Health Outcomes. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
- July 2003 Evaluation of p53 Immunoreactivity in African-American Patients with Breast Cancer. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
- July 2003 Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Patients is Associated with Inadequate Screening Practice. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
- October 2003 Outcome Disparity for Preoperative or Neoadjuvant Chemotherapy in African-American Breast Cancer Patients. AACR Special Conference, Advances in Breast Cancer Research: Genetics, Biology & Clinical Applications, Huntington Beach, CA.
- October 2003 p53 Immunostaining in African-American Breast Cancer Patients is Significantly Associated with Higher Stage & Negative Hormone Receptor Status. AACR Special Conference, Advances in Breast Cancer Research: Genetics, Biology & Clinical Applications, Huntington Beach, CA.
- November 2003 The Significance of p53 Immunoreactivity in African-American Patients with Breast Cancer. The Association for Cancer Surgery at the Royal College of Surgeons of England, London, UK.
- December 2003 Technical differences contribute to hormone receptor negative status in African-American underserved patients. The 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- December 2003 ER beta expression parallels ER alpha/ PR expression and is inversely related to EGFR expression in African American women with breast cancer. The 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- March 2004 HER2/neu Status in African-American Women with Breast Cancer. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
- March 2004 Early Stage Interval Breast Cancers in African-American Women Demonstrate ER Negative Status & More Aggressive Tumor Biology. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
- March 2004 Poor Quality Reporting of Screening Mammography is Associated with Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Women. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
- May 2004 Delivering the Continuum of Breast Cancer Care to the Underserved: Treatment Issues. 2nd annual Avon Symposium at UCSF Comprehensive Cancer Center, San Francisco, CA.
- December 2004 Improved yield of perioperative screening for metastases in African-American women with operable breast cancer. The 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- December 2004 Analysis of hormone receptor function in African-American women with breast cancer. The 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- April 2005 HER2/neu overexpression and survival in African-American women with breast cancer. The 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
- April 2005 Health attitudes, beliefs and habits affect breast cancer screening practice among minority-underserved and low income women. The 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
- December 2005 Low socio-economic status African-American, Hispanic White women with breast cancer demonstrate similar hormone receptor status, tumor grade survival. The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- January 2006 Management of common and benign breast disease. Basic Science Surgical Lecture series at Department of Surgery, University of Illinois at Chicago.
- March 2006 Management of ductal carcinoma in situ. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- April 2006 Management of invasive breast cancer. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- April 2006 Underserved African-American & white women with breast cancer have similar prognostic profiles for estrogen receptor and tumor grade. The 97th annual meeting of the American Association for Cancer Research, Washington, DC.

- June 2006 p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. The 2006 Annual meeting of the American Society of Clinical Oncology, Atlanta, GA.
- September 2006 p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer. AACR Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment, Chicago, IL.
- November 2006 Management of common and benign breast disease. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- November 2006 Management of women at high-risk for breast cancer. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- November 2006 Management of ductal carcinoma in situ. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- November 2006 Management of invasive breast cancer. Basic Science Surgical Lecture series at Department of Surgery, UIC.
- December 2006 p53 gene mutations in African-American women with breast cancer. The 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
- April 2007 Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. The 2007 Annual meeting of the American Association for Cancer Research, Los Angeles, CA.
- May 2007 MBCCOP Stroger Hospital, Program Evolution and Results of the Correlative Science Project. Special presentation, Center for Researching & Reducing Cancer Health Disparities, NCI, Rockville, MD.
- June 2007 Absence of racial predilection for aggressive tumor phenotype among low socio-economic status women with breast cancer. The 2007 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
- September 2007 Poverty predicts aggressive breast cancer phenotype and poor prognosis. The 2007 Joint American Society of Clinical Oncology/ Society of Surgical Oncology, Breast Cancer Symposium, San Francisco, CA.
- November 2007 The interaction of race, low socioeconomic status and ER negative type tumor biology. Estrogen Receptor Negative Breast-Cancer-Workshop. National Cancer Institute, Bethesda, MD.
- April 2008 Worsening degree of poverty predicts increased likelihood of ER/PR negative, triple negative & basal breast cancer subtypes. The 2008 Annual meeting of the American Association for Cancer Research, San Diego, CA.
- September 2008 Further stratification of breast cancer survival in younger African American (AA) women using p53 as an additional marker to the intrinsic subtype classification. The 2008 Annual meeting of the American Society of Clinical Oncology, Breast Cancer Symposium, Washington, DC.
- March 2009 p53 as a marker of prognosis in African-American women with breast cancer: Is it ready for prime time? Abbott Laboratories Physician Development Program Seminar, Abbott Park, IL.
- April 2009 Recommendations for improvement in technology transfer at H. Lee Moffitt Cancer Center – University of Chicago Booth School of Business Management Laboratory presentation to the Moffitt Executive Board, Moffitt Cancer Center, Tampa, FL.
- June 2009 Recommendations for personalized medicine and targeted therapy phase 1-2 cancer trials CRO (feasibility and business development model) at H. Lee Moffitt Cancer Center – Presentation to the Executive Board, Moffitt Cancer Center, Tampa, FL.
- July 2009 The role of p53 for prognosis in low SES African-American women with breast cancer: Is it better than subtype? Abbott Labs. Oncology Seminar, Abbott Park, IL.
- April 2010 Race-based survival and prognosis among lower SES women with ER/PR negative breast cancer. The 2010 Annual meeting of the American Association for Cancer Research, Washington, DC.
- June 2010 Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. The 2010 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
- June 2011 The influence of sociodemographic factors on breast cancer tumor biology. The 2011 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
- June 2012 The history of prior screening mammography and risk of mastectomy among women with breast cancer. The 2012 Annual Meeting of the Society for Epidemiologic Research, Minneapolis, MN.
- May 2013 Outcomes Following Implementation of 2010 CDC Chorioamnionitis Guidelines in Neonates. The 2013 Pediatric Academic Societies Meeting, Washington, D.C.
- December 2013 Race/ethnicity and disparities in mastectomy use in the Breast Cancer Care in Chicago Study. The 6th AACR Annual Conference on the Science of Cancer Health Disparities, Atlanta, GA.
- March 2014 Is p53 an independent marker of aggressiveness in an ethnically diverse sample of breast cancer patients, after accounting for molecular subtype? The 103rd USCAP Annual Meeting, San Diego, CA.
- November 2014 Exploring the role of reproductive factors and DNA methylation in ethnic disparities in breast cancer tumor aggressiveness. The 7th AACR Annual Conference on the Science of Cancer Health Disparities, San Antonio, TX.
- April 2015 The influence of *KCNK9* on the black/white triple negative breast cancer disparity. The NIH Centers for Population Health and Health Disparities 2015 Annual Meeting, Chapel Hill, NC.
- May 2015 Characterization of *KCNK9* in *The Cancer Genome Atlas* breast cancer dataset. The 2015 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
- November 2015 Exploring disparities in sentinel lymph node biopsy within the Breast Cancer Care in Chicago study. The 8th AACR Annual Conference on the Science of Cancer Health Disparities, Atlanta, GA.
- November 2015 The role of *KCNK9* and *TP53* on the racial disparity in biologically aggressive breast cancer subtype in *The Cancer Genome Atlas* (TCGA). The 8th AACR Annual Conference on the Science of Cancer Health Disparities, Atlanta, GA.
- May 2016 Clinical outcomes associated with a failed infant car seat challenge. The 2016 Pediatric Academic Societies Meeting, Baltimore, MD.
- September 2016 Two-pore domain potassium channel genes and triple negative subtype in *The Cancer Genome Atlas* breast cancer dataset. The 9th AACR Annual Conference on the Science of Cancer Health Disparities, Fort Lauderdale, FL.

- May 2017 Severity of disease accounts for early mortality difference between inborn and outborn infants treated with therapeutic hypothermia for neonatal encephalopathy. The 2017 Pediatric Academic Societies Meeting, San Francisco, CA
- May 2017 Analysis of factors predictive of abnormal MRI in infants with hypoxic-ischemic encephalopathy treated with hypothermia. The 2017 Pediatric Academic Societies Meeting, San Francisco, CA.

SESSION CHAIRS/ PRECEPTORSHIPS/ VISITING PROFESSORSHIPS/ PANELS:

- January 1998 Surgical preceptorship: Advanced Breast Biopsy Instrumentation (ABBI) procedures. Forbes Regional Hospital, Pittsburgh, PA.
- Jan/Feb 1999 Surgical preceptorship: ABBI procedures. The University of South Florida & Moffitt Cancer Center radioguided surgery & minimally invasive breast biopsy course, Moffitt Cancer Center, Tampa, FL.
- March 2001 Visiting Professor: Department of Radiology, University of the West Indies School of Medicine, Mt. Hope, Trinidad, W.I.
- July 2003 Panel: Clinical Research in Minorities and the Medically Underserved Minisymposium. The 94th Annual Meeting of the American Association for Cancer Research, Washington, DC.
- May 2004 Session Chair: Delivering the Continuum of Breast Cancer Care to the Underserved: Treatment Issues. 2nd annual Avon Symposium at UCSF Comprehensive Cancer Center, San Francisco, California.
- April 2005 Session Chair: Breast Cancer in African-American Women. Avon Foundation Breast Care Fund Discussion Forum.
- April 2006 Panel: The American Association for Cancer Research, Health Disparities Panel & Press Conference. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC.
- June 2006 Panel: Role of Biological Differences in Cancer Outcome Disparities in Racial and Ethnic Minorities, Clinical Science Symposium. The 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA.
- June 2006 Panel: Angiogenesis and targeted therapy: New approaches to breast cancer. Dawn of New Therapies Cancer Symposium, University of Illinois at Chicago, Chicago, IL.
- April 2007 Panel: Health Disparities and Epidemiology Mini-symposium. The 2007 American Association for Cancer Research Annual Meeting, Los Angeles, CA.
- November 2007 Panel: Estrogen Receptor Negative Breast-Cancer-Workshop. National Cancer Institute, Bethesda, MD.
- April 2010 Panel: MICR Professional Advancement Roundtable: 'Navigating the Road to a Successful Career in Cancer Research'. The 2010, 101st American Association for Cancer Research, Annual Meeting, Washington, DC.

PUBLICATIONS:

A. Original Investigations

1. Dookeran KA, Thompson MM, Lloyd DM, Everson NW. Audit of general practitioner referrals to an acute surgical unit: Can the system be improved? *Br. J. Surg.* 1992;79:430-32.
2. Thompson MM, Underwood M, Dookeran KA, Lloyd DM, Bell PRF. The role of sequential leukocyte count & CRP measurement in acute appendicitis. *Br. J. Surg.* 1992;79:822-24.
3. Thompson MM, Underwood M, Sayers R, Dookeran KA, Bell PRF. Peripheral tuberculous lymphadenopathy: A review of 67 cases. *Br. J. Surg.* 1992;79:763-64.
4. Dookeran KA, Stotter A, Windle R, Walker RA. Treating elderly patients with breast cancer. *B.M.J.* 1992;304:1376-77.
5. Dookeran KA, Thompson MM, Allum WH. Pancreatic insufficiency secondary to abdominal radiotherapy. *Eur. J. Surg. Oncol.* 1993;19:95-6.
6. Rye PD, Dookeran KA, Walker RA. Expression of the pS2 peptide in normal human glandular endometrium during the menstrual cycle: A possible function. *Disease Markers* 1993;11:23-8.
7. Dookeran KA, Rye PD, Walker RA. Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns. *J. Path.* 1993;171:123-29.
8. Walker RA, Denley H, Dookeran KA. Cathepsin D in breast carcinomas - The role of the stromal cell component. *Oncology Reports* 1994;1:227-31.
9. Dookeran KA, Nottingham JF, Bajallan N, Memon F, Bullen BR. Carcinoid tumor presenting with caecal infarction. *Br. J. Surg.* 1994;81:1658.
10. Dookeran KA & Sikora SS. Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. *Br. J. Surg.* 1995;82:712-16.
11. Walker RA, Rajakariar R, Dookeran KA. Comparison of pS2 and Cathepsin D in primary breast carcinomas. *The Breast* 1995;4:137-42.
12. Dookeran KA & Sikora SS. How should the axilla be treated in breast cancer? *Eur. J. Surg. Oncol.* 1995;21:435-6.
13. Dookeran KA, Bain I, Moshakis V. Audit of General Practitioner Referrals to an Acute Surgical Unit: New Methods to improve the Service. *Br. J. Surg.* 1996;83:1544-47.
14. Sikora SS, Samsonov ME, Dookeran KA, Edington H, Lotze MT. Peripheral Nerve Environment: An unusual adverse event with high dose systemic interleukin-2 therapy. *Ann. Oncol.* 1996;7:535-6.
15. Dookeran KA, Lotze MT, Sikora SS, Rao U. Pancreatic and ampullary carcinomas with intrascrotal metastases. *Br. J. Surg.* 1997;84:198-9.
16. Dookeran KA, Brumfield A, Rubin JT. A comparison of locoregional depot and systemic preparations of 9aminocamptothecin for treatment of liver metastases in a rat tumor model: Superior antitumor activity of sustained-release preparation. *Ann. Surg. Oncol.* 1997;4:355-60.

17. Iwazawa T, Chau CY, Mori T, Dookeran KA, Rubin JT, Watkins S, Robbins PD, Lotze MT, Tahara H. Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in a rat liver metastasis model: No additional benefit of using retroviral producer cells. *Cancer Gene Therapy* 2001;8:17-22.
18. Dupont EL, Kamath VJ, Ramnath EM, Shivers SC, Cox C, Berman C, Leight GS, Ross MI, Blumencranz P, Reintgen DS, and the *DOD Breast Lymphatic Mapping Trial Investigators (*includes Dookeran KA). The Role of Lymphoscintigraphy in the Management of the Patient With Breast Cancer. *Ann. Surg. Oncol.* 2001;8:354-360.
19. Shivers SC, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross MI, Reintgen DS, and the *DOD Lymphatic Mapping Investigators (*includes Dookeran KA). Final Results of the Department of Defense Multicenter Breast Lymphatic Mapping Trial. *Ann. Surg. Oncol.* 2002;9:248-255.
20. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the *International Breast Cancer Study Group (*includes Dookeran KA). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Ann. Oncol.* 2008;19(7):1231-41.
21. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African-American women with breast cancer. *Ann. Surg. Oncol.* 2010;17:1398-1405. (DOI: 10.1245/s10434-009-0889-3).
22. Dookeran KA, Dignam J, Holloway N, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. Race and the prognostic influence of p53 in women with breast cancer. *Ann. Surg. Oncol.* 2012;19:2334-2344. (DOI 10.1245/s10434-011-1934-6).
23. Dookeran KA, Silva A, Warnecke R, Rauscher GH. Race/ethnicity and disparities in mastectomy practice in the Breast Cancer Care in Chicago Study. *Ann. Surg. Oncol.* 2015;22:66-74. (DOI: 10.1245/s10434-014-3945-6).
24. Smith CE, Fullerton SM, Dookeran KA, Hampel H, Tin A, Maruthur NM, Schisler JC, Henderson JA, Tucker KL, and Ordovas JM. Using genetic technologies to reduce, rather than widen, health disparities. *Health Affairs.* 2016;35(8):1367-1373. doi:10.1377/hlthaff.2015.1476.
25. Shah M, Dookeran KA, Khan JY. Clinical outcomes associated with a failed infant car seat challenge. *Journal of Pediatrics* 2017;180:130-134. <http://dx.doi.org/10.1016/j.jpeds.2016.09.072>
26. Dookeran KA, Zhang W, Stayner L, and Argos M. Associations of 2-pore domain potassium channel genes and breast cancer subtype in The Cancer Genome Atlas: a systematic evaluation of gene expression and methylation. *BMC Research Notes* 2017. DOI: [10.1186/s13104-017-2777-4](https://doi.org/10.1186/s13104-017-2777-4).

B. Books Chapters, Reviews, Case Reports, Letters, Editorials

1. Rubin JT, Dookeran KA. Infusional therapy of metastatic tumors of the liver. In: *Regional therapy of advanced cancer* (ISBN: 9780397514748). Eds: Lotze MT, Rubin JT. Publishers: Lippincott-Raven, Philadelphia, 1997:119-128.
2. Dookeran KA. Morbidity following Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection for Patients with Breast Carcinoma. *Breast Diseases: A Year Book Quarterly* 2000;11:313.
3. Dookeran KA. National Cancer Data Base Survey of Breast Cancer Management for Patients from Low Income Zip Codes. *Breast Diseases: A Year Book Quarterly* 2000;11:343-4.
4. Dookeran KA. Socioeconomic Factors, not Ethnicity, Predict Breast Self-Examination. *Breast Diseases: A Year Book Quarterly* 2001;12:126.
5. Dookeran KA. Effect of Health Insurance and Race on Breast Carcinoma Treatments and Outcomes. *Breast Diseases: A Year Book Quarterly* 2001;12:239-40.
6. Dookeran KA. The Effect of Less Than Definitive Care on Breast Carcinoma Recurrence and Mortality. *Breast Diseases: A Year Book Quarterly* 2001;12:241.
7. Dookeran KA. Use of Coping Strategies and Breast Cancer Survival: Results from the Black/ White Survival Study. *Breast Diseases: A Year Book Quarterly* 2001;12:241.
8. Dookeran KA. Breast Cancer Outcomes Among Older Women. *Breast Diseases: A Year Book Quarterly* 2002;12:441-2.
9. Dookeran KA. Breast Reconstruction Among Inner City Women With Breast Carcinoma. *Breast Diseases: A Year Book Quarterly* 2002;13:98-9.
10. Dookeran KA. Extranodal Extension of Axillary Metastases of Invasive Breast Carcinoma as a Possible Predictor for the Total Number of Positive Lymph Nodes. *Breast Diseases: A Year Book Quarterly* 2002;13:248.
11. Dookeran KA. Breast Carcinoma Treatment Received by Women with Disabilities Compared with Women without Disabilities. *Breast Diseases: A Year Book Quarterly* 2003;14:37.
12. Dookeran KA. Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer. *Breast Diseases: A Year Book Quarterly* 2003;14:55.
13. Dookeran KA. Differences in Breast Cancer Hormone Receptor Status and Histology by Race and Ethnicity among Women 50 Years of Age and Older. *Breast Diseases: A Year Book Quarterly* 2003;14:31-2.
14. Dookeran KA. Racial/Ethnic Differences in Survival Rates in a Population-Based Series of Men with Breast Carcinoma. *Breast Diseases: A Year Book Quarterly* 2003;14:36.
15. Dookeran KA. Racial Differences in Treatment and Survival from Early-Stage Breast Carcinoma. *Breast Diseases: A Year Book Quarterly* 2003;14:272-3.
16. Dookeran KA. Recent Trends and Racial/Ethnic Differences in the Incidence and Treatment of Ductal Carcinoma In Situ of the Breast in California Women. *Breast Diseases: A Year Book Quarterly* 2003;14:267-9.

17. Dookeran KA. Differences in Treatment Patterns for Localized Breast Carcinoma among Asian/Pacific Islander Women. *Breast Diseases: A Year Book Quarterly* 2003;14:272.
18. Dookeran KA. Atypical Ductal Hyperplasia of the Breast Diagnosed by 11-gauge Directional Vacuum-Assisted Biopsy. *Breast Diseases: A Year Book Quarterly* 2003;14:312-13.
19. Dookeran KA. Socioeconomic Status and Breast Carcinoma Survival in Four Racial/Ethnic Groups: A Population-Based Study. *Breast Diseases: A Year Book Quarterly* 2004;15:91-92.
20. Dookeran KA. Surgical Outcomes of a Breast Cancer–Screening Program for Low-Income Women. *Breast Diseases: A Year Book Quarterly* 2004;15:171-172.
21. Dookeran KA. Does re-operation predispose to postoperative wound infection in women undergoing operation for breast cancer? *Breast Diseases: A Year Book Quarterly* 2004;15:298-9.
22. Dookeran KA. Evidence That Extremes in Diet Are Associated With Poor Survival. *Breast Diseases: A Year Book Quarterly* 2004;15:288.
23. Dookeran KA. Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. *Breast Diseases: A Year Book Quarterly* 2005;15:371-2.
24. Dookeran KA. BRCA1 and BRCA2 Mutations in Women from Shanghai China. *Breast Diseases: A Year Book Quarterly* 2005;15:378.
25. Dookeran KA. Racial Differences in the Use of BRCA1/2 Testing Among Women with a Family History of Breast or Ovarian Cancer. *Breast Diseases: A Year Book Quarterly* 2006;16:334-5.
26. Dookeran KA. The Roles of Teaching Hospitals, Insurance Status, and Race/Ethnicity in Receipt of Adjuvant Therapy for Regional-Stage Breast Cancer in Florida. *Breast Diseases: A Year Book Quarterly* 2007;17:339.
27. Dookeran KA. Racial Differences in Pain During 1 Year Among Women With Metastatic Breast Cancer: A Hazards Analysis of Interval-Censored Data. *Breast Diseases: A Year Book Quarterly* 2008;19:132-33.
28. Dookeran KA. Racial and Ethnic Differences in Breast Cancer Survival Breast Diseases: How Much Is Explained by Screening, Tumor Severity, Biology, Treatment, Comorbidities, and Demographics? *A Year Book Quarterly* 2008;19:133-35.
29. Dookeran KA. Factors Associated with Advanced Disease Stage at Diagnosis in a Population-based Study of Patients with Newly Diagnosed Breast Cancer. *Breast Diseases: A Year Book Quarterly* 2008;19:242-3.
30. Dookeran KA. Disparities in Medical Care Among Commercially Insured Patients with Newly Diagnosed Breast Cancer. *Breast Diseases: A Year Book Quarterly* 2010;21:217-8.
31. Dookeran KA. Age/Race Differences in HER2 Testing and in Incidence Rates for Breast Cancer Triple Subtypes. *Breast Diseases: A Year Book Quarterly* 2011;21:338-40.
32. Dookeran KA. Improving on National Quality Indicators of Breast Cancer Care in a Large Public Hospital as a Means to Decrease Disparities for African American Women. *Breast Diseases: A Year Book Quarterly* 2011;22:258-9.
33. Dookeran KA. Race-Specific Impact of Natural History, Mammography Screening, and Adjuvant Treatment on Breast Cancer Mortality Rates in the United States. *Breast Diseases: A Year Book Quarterly* 2012; 22:362-4.
34. Dookeran KA. Racial Variation in Breast Cancer Treatment Among Department of Defense Beneficiaries. *Breast Diseases: A Year Book Quarterly* 2013; 23:330-1.

C. Abstracts

1. Dookeran KA, Dearing S, Rye PD, Windle R, Stotter A, Walker RA. pS2 immunohistochemical staining in breast cancer: positive correlation with endocrine response. *Eur. J. Surg. Oncol.* 1992;18-4:403.
2. Walker RA, Dearing S, Rye PD, Dookeran KA. The significance of pS2 immunoreactivity in primary breast carcinomas. *J. Path.* 1992;167:131.
3. Dookeran KA & Thompson MM. Audit of general practitioner referrals to an acute surgical unit. *Br. J. Surg.* 1992;79:1111.
4. Dookeran KA, Walker RA, Dearing S, Rye PD, Stotter A, Windle R. The significance of pS2 luminal immunoreactivity in breast cancer. *Br. J. Surg.* 1992;79:1237-38.
5. Dookeran KA, Dearing S, Stotter A, Windle R, Walker RA. Evaluation of pS2 expression in primary breast tumors: prediction of response to endocrine therapy. *Br. J. Cancer* 1992;66-XVII:8.
6. Dookeran KA, Stotter A, Windle R, Walker RA. The value of pS2 expression in predicting response to endocrine therapy in moderately and poorly differentiated primary breast tumors. *Irish Jour. Med. Sci.* 1992;161:17.
7. Dookeran KA, Dearing S, Stotter A, Windle R, Walker RA. pS2 expression in primary breast tumors: prediction of response to endocrine therapy. *The Breast* 1992;1:155.
8. Walker RA, Denley H, Dookeran KA. Comparison of pS2 and Cathepsin D expression in breast carcinomas. *J. Path.* 1993;169:154.
9. Dookeran KA, Walker RA, Windle R, Stotter A. pS2 immunoreactivity in primary breast tumors: the significance of luminal & cytoplasmic staining. *Eur. J. Surg. Oncol.* 1993;19:97.
10. Dookeran KA, Denley H, Dearing S, Stotter A, Walker RA, Windle R. Cathepsin D & pS2 expression in breast tumors: Relationship with response to endocrine therapy. *Eur. J. Surg. Oncol.* 1993;19:214-15.
11. Rubin JT, Brumfield A, Dookeran KA, Lotze MT. Tumour targeted delivery of sustained release, high dose 9-aminocamptothecin. *Proc. AACR* 1995;36:452.
12. Dookeran KA, Brumfield A, Lotze MT, Rubin JT. Eradication of hepatic metastases with intra-hepatic arterial infusion of sustained release 9-aminocamptothecin. *The Annual Surgical Forum Volume of the 81st Clinical Congress of the American College of Surgeons* 1995;XLVI:158.

13. Dookeran KA, Brumfield A, Lotze MT, Rubin JT. Effective therapy of hepatic metastases with intra-hepatic arterial infusion of sustained release interleukin-2. *Journal of Immunotherapy* 1995;18:132.
14. Dookeran KA, Brumfield A, Lotze MT, Rubin JT. Therapy of hepatic metastases with intra-hepatic arterial infusion of sustained release interleukin-2 in ethiodol. *Biological Therapy of Cancer* 1995;X:38.
15. Dookeran KA, Brumfield A, Rubin JT. Antitumor activity of intra-hepatic arterial 9-aminocamptothecin and ethiodol exceeds that of systemic (Colloidal dispersion) 9-aminocamptothecin. The 49th Cancer Symposium of the Society Surgical Oncology meeting abstract book 1996;P#87:59.
16. Dookeran KA, Shipe-Spotloe J, Sikora SS, Rubin JT, Kirkwood JM, Lotze MT, Logan T. Low dose systemic interleukin-2 regimens in patients with significant co-morbid illness. *Proc. AACR* 1996;37:488.
17. Chau G, Dookeran KA, Brumfield A, Teuting T, Lotze MT, Rubin J. Effective antitumor activity of IFN- α in animal models. The 30th Annual meeting of the Association for Academic Surgery Abstract Book 1996;9:38.
18. Iwazawa T, Chau G, Dookeran KA, Robbins P, Rubin JT, Lotze MT, Tahara H. Effective gene therapy of murine breast cancer liver metastases with IL-12. The 50th Cancer Symposium of the Society of Surgical Oncology meeting abstract book 1997;A#48:18.
19. Dookeran KA, Hanan S, Chau G, Brumfield A, Edwards J, Lotze MT, Rubin JT. Locoregional therapy of cancer with Nitric Oxide donors delivered in Ethiodol. The 50th Cancer Symposium of the Society of Surgical Oncology meeting abstract book 1997;P#53:48.
20. Dookeran KA, Hanan S, Brumfield A, Edwards J, Lotze MT, Rubin JT. Effective antitumor activity of Taxol in Ethiodol. *Proc. AACR* 1997;38:260.
21. Hanan S, Dookeran KA, Rao U, Rubin JT, Logan T. Recombinant human TNF α produces neutrophil nadir in peripheral blood and hemorrhagic necrosis in syngenic murine breast carcinoma model. *Proc. AACR* 1997;38:489.
22. Dookeran KA. Audit of general practitioner referrals to a Surgical Assessment Unit: new methods to the efficiency of the acute Surgical Service. *Br. J.Surg* 1997;84:727-728.
23. Bleicher RJ, Tokarsky JM, Zaren HA, Dookeran KA. Adjuvant chemotherapy for breast cancer administered by surgical or medical oncologists: No difference in therapy. 66th Annual Scientific meeting of the Southeastern Surgical Congress poster session abstract book 1998; P#12.
24. Dookeran KA, Hanan S, Lotze MT. Effective regional therapy of cancer with sustained-release, Nitric Oxide-donor, Nitroprusside in Ethiodol. The 51st Cancer Symposium of the Society of Surgical Oncology meeting abstract book 1998;P#36:57.
25. Dookeran KA, Rao U, Borochoviz D, Zaren HA, Rajakumar PA. Relationship of glucose transporter 1 and p53 expression in human breast cancer. *Proc. AACR* 1998;39:621.
26. Dookeran KA, Poller WR, Tokarsky JM, Turkas DJ, Borochoviz D, Zaren HA. The role of ABBI biopsy in patients with mammographic abnormalities. *Eur. J. Surg. Oncol.* 1998;24:350.
27. Dookeran KA, Rao U, Borochoviz D, Zaren HA, Rajakumar PA. Parallel expression of glucose transporter 1 and p53 in primary breast cancer. *Eur. J. Surg. Oncol.* 1998;24:354.
28. Dookeran KA, Poller WR, Turkas DJ, Tokarsky JM, Borochoviz D, Zaren HA. Prospective evaluation of the Advanced Breast Biopsy (ABBI) System as a method for stereotactic breast biopsy of mammographic non-palpable abnormalities. *Radiology* 1998;209 (P):524.
29. McDonald K, Poller WR, Rajakumar PA, Zaren HA, Dookeran KA. The efficacy of combined dye approach in identifying Sentinel nodes in patients with breast cancer. *Radiology* 1998;209 (P):441,523.
30. Dookeran KA, Rao U, Borochoviz D, Chappano PJ, Rajakumar PA, Zaren HA. Relationship of glucose transporter 1 and cerb-B2 in primary human breast cancer. The 32nd Annual meeting of the Association for Academic Surgery Abstract Book 1998;201:P1
31. Dookeran KA, Madden JW, Poller WR, Chappano PJ, Tokarsky JM, Turkas DJ, Borochoviz D, Zaren HA. Analysis of eligibility criteria for ABBI procedures in patients with non-palpable mammographic abnormalities. 67th Annual Scientific meeting of the Southeastern Surgical Congress Residents Forum abstract book 1999;12:#7.
32. Madden JW, Rajakumar PA, Rao U, Borochoviz D, Chappano PJ, Cowans R, Zaren HA, Dookeran KA. Relationship of Glucose Transporter 1 and Cathepsin-D in human primary breast cancer. 67th Annual Scientific meeting of the Southeastern Surgical Congress poster session abstract book 1999; P#51.
33. Chappano PJ, Sunderman JM, Orchard J, Cowans R, Zaren HA, Rajakumar PA, Dookeran KA. p53 and Glucose Transporter 1 expression in chronic active gastritis associated with Helicobacter Pylori infection. 67th Annual Scientific meeting of the Southeastern Surgical Congress poster session abstract book 1999; P#43.
34. Dookeran KA, Borochoviz D, McDonald K, Zaren HA. Correlation of touch preparation cytology, conventional histology and cytokeratin immunohistochemistry for sentinel lymph nodes in patients with breast cancer. *Proc. AACR* 1999;40:494.
35. Dookeran KA & Zaren HA. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. *Proc. ASCO* 1999;18:72a.
36. Dookeran KA. Mechanisms of antitumor activity for sustained-release nitric-oxide donor, Nitroprusside in Ethiodol. *Proc. AACR* 2000;41:280.
37. Dookeran KA, Rossi H, Shin F, Tran H, Mullai N, Samuel J, Catchetorian R, Zaren HA. Prognostic differences for African-American and other medically-underserved patients with breast cancer. *Proc. AACR* 2001;42:890.
38. Babu L, Agbemadzo B, Mullai N, Samuel J, Dissanayake R, Kio E, Subramaniam D, Dookeran KA, Zaren HA. Incidence of breast cancer in patients less than 40 years old in a minority-based urban hospital. *Proc. ASCO* 2001;20:36b.
39. Samuel J, Mullai N, Dissanayake R, Agbemadzo B, Kio E, Subramaniam D, Dookeran KA, Zaren HA. Demographics of breast cancer in a minority-based institution. *Proc. ASCO* 2001;20:323b.
40. Dissanayake R, Mullai N, Samuel J, Agbemadzo B, Kio E, Subramaniam D, Dookeran KA, Zaren HA, Ramadurai J. Correlation of estrogen receptor (ER) and HER2/neu (HER2) overexpression in breast cancer patients. *Proc. ASCO* 2001;20:328b.

41. Mullai N, Samuel J, Dissanayake R, Agbemadzo B, Subramaniam D, Kio E, Dookeran KA, Zaren HA. Discordance in prognostic factor analysis in breast core biopsies vs. surgical specimens. *Proc. ASCO* 2001;20:338b.
42. Dookeran KA, Rossi H, Tran H, Shin F, Catchetourian R, Samuel J, Mullai N, Zaren HA. Differences in breast cancer management outcomes for African-American and other medically-underserved patients. *Proc. ASCO* 2001;20:216b.
43. Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Shin F, Rogowski W, Tran H, Yang J, McFarlin M, Reed A, Sekosan M, Catchatourian R, Zaren HA. Comparison of prognostic factors for minority-underserved patients with breast cancer. *Proc. AACR* 2002;43:238.
44. Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Shin F, Tran H, Rogowski W, Yang J, Reed A, McFarlin M, Sekosan M, Catchatourian R, Zaren HA. Outcomes for breast cancer screening & early detection in minority-underserved women. *Proc. AACR* 2002;43:238.
45. Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Tran H, Rogowski W, Yang J, Sekosan M, Catchatourian R, Zaren HA. Analysis of results for breast cancer screening & early detection in minority-underserved American women. *Eur. J. Surg. Oncol.* 2002;28:329.
46. Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. A comparison of prognostic factors for minority-underserved American patients with breast cancer. *Eur. J. Surg. Oncol.* 2002;28:334-5.
47. Yang J, Dookeran KA, Sekosan M, Sciupokiene E, Rogowski W, Tran H, Catchatourian R, Zaren HA. African-American women with breast cancer are more likely to be ER-beta positive. *Proc. ASCO* 2002;21:289b.
48. Dookeran KA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. HER-2/neu overexpression in African-American women with breast cancer is not associated with negative ER status or higher stage disease. *Proc. ASCO* 2002;21:296b.
49. Zaren HA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Dookeran KA. Minority-underserved women with breast cancer do not receive worse treatment on NCI studies. *Proc. ASCO* 2002;21:45b.
50. Dookeran KA, Yang J, Sekosan M, Sciupokiene E, Rogowski W, Tran H, Catchatourian R, Zaren HA. Black women with breast cancer are more likely to be ER-beta positive. *Br. J. Cancer* 2002;86:S39.
51. Dookeran KA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. Her-2/Neu overexpression in Black women with breast cancer is not associated with negative ER status or higher stage disease. *Br. J. Cancer* 2002;86:S39.
52. Dookeran KA, Sciupokiene E, Rogowski WA, Elfarrar G, Caluser C, Yang J, Sekosan M, Catchatourian R, Zaren HA. Fine needle aspirate biopsies of breast lesions are more commonly unsatisfactory and inaccurate when performed by non-surgeons. *Breast Cancer Research & Treatment* 2002;76:S39.
53. Dookeran KA, Sciupokiene E, Mackeviciute A, Elfarrar G, Rogowski WA, Patel J, Ruestow P, Zaren HA. Minority-Underserved Women Treated for Breast Cancer Are at Increased Risk for Poor Mental Health Outcomes. *Proc. AACR* 2003;44:185.
54. Dookeran KA, Gao X, Ferrer K, Sekosan M, Kumar B, Yang J, Sciupokiene E, Mackeviciute A, Rogowski WA, Catchatourian R, Zaren HA. Evaluation of p53 Immunoreactivity in African-American Patients with Breast Cancer. *Proc. AACR* 2003;44:295.
55. Dookeran KA, Sciupokiene E, Mackeviciute A, Rogowski WA, Elfarrar G, Patel J, Ruestow P, Lavelle MB, Caluser C, Kumar B, Gao X, Yang J, Ferrer K, Sekosan M, Catchatourian R, Zaren HA. Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Patients is Associated with Inadequate Screening Practice. *Proc. AACR* 2003 44:295.
56. Sciupokiene E, Koko I, Dookeran KA, Mackeviciute A, Rogowski WA, Yim B, Catchatourian R, Zaren HA. Factors influencing non-compliance with systemic chemotherapeutic regimens for breast cancer among minority-underserved women. *Proc. ASCO* 2003;22:90.
57. Zaren HA, Sciupokiene E, Mackeviciute A, Rogowski WA, Elfarrar G, Muthyala N, Patel J, Carter M, Ubaka J, Dookeran KA. Recruitment & Retention of Minority-Underserved Participants to the Star/P2 Study is Difficult. *Proc. ASCO* 2003;22:94.
58. Dookeran KA, Gao X, Ferrer K, Sekosan M, Yang J, Kumar B, Sciupokiene E, Mackeviciute A, Rogowski WA, Zaren HA. HER-2/neu & EGFR Status in African-American Patients with Breast Cancer. *Proc. ASCO* 2003;22:904.
59. Zaren HA, Sciupokiene E, Mackeviciute A, Ferrer K, Sekosan M, Caluser C, Koko I, Petrosyan M, Pei K, Muthyala N, Rogowski WA, Dookeran KA. Outcome Disparity for Preoperative or Neoadjuvant Chemotherapy in African-American Breast Cancer Patients. *AACR Conference: Advances in Breast Cancer Research Proceedings* 2003:B40.
60. Dookeran KA, Gao X, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute A, Muthyala N, Rogowski WA, Zaren HA. p53 Immunostaining in African-American Breast Cancer Patients is Significantly Associated with Higher Stage & Negative Hormone Receptor Status. *AACR Conference: Advances in Breast Cancer Research Proceedings* 2003:A12.
61. Dookeran KA, Gao X, Ferrer K, Sekosan M, Yang J, Sciupokiene E, Mackeviciute A, Rogowski WA, Muthyala N, Zaren HA. The Significance of p53 Immunoreactivity in African-American Patients with Breast Cancer. *Eur. J. Surg. Oncol.* 2003;29:829-30.
62. Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute A, Rogowski WA, Muthyala N, Koko I, Zaren HA. Technical differences contribute to hormone receptor negative status in African-American underserved patients. *Breast Cancer Research & Treatment* 2003;82:S61-2.
63. Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute A, Zaren HA. ER beta expression parallels ER alpha/PR expression and is inversely related to EGFR expression in African American women with breast cancer. *Breast Cancer Research & Treatment* 2003;82:S63.
64. Dookeran KA, Sciupokiene E, Ferrer K, Sekosan M, Mackeviciute A, Gao X, Elfarrar G, Wang Y, Rogowski WA, Muthyala N, Zaren HA. HER2/neu Status in African-American Women with Breast Cancer. *Proc. AACR* 2004;45:1213,#5261.
65. Dookeran KA, Sciupokiene E, Mackeviciute A, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Elfarrar G, Wang Y, Rogowski WA, Muthyala N, Caluser C, Zaren HA. Early Stage Interval Breast Cancers in African-American Women Demonstrate ER Negative Status & More Aggressive Tumor Biology. *Proc. AACR* 2004;45:1213,#5259.

66. Dookeran KA, Sciupokiene E, Mackeviciute A, Elfarra G, Wang Y, Rogowski WA, Muthyala N, Caluser C, Gao X, Ferrer K, Sekosan M, Zaren HA. Poor Quality Reporting of Screening Mammography is Associated with Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Women. *Proc. AACR* 2004;45:1213,#5260.
67. Zaren HA, Sciupokiene E, Mackeviciute A, Gao X, Ferrer K, Wang Y, Zhang S, Sekosan M, Dookeran KA. African-American women with breast cancer treated with preoperative chemotherapy have reduced pathologic complete response rates. *Proc. ASCO* 2004;23:94,#876.
68. Dookeran KA, Gao X, Ferrer K, Sciupokiene E, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Sekosan M, Zaren HA. Tumor biology in African-American women with breast cancer treated with preoperative chemotherapy: lack of pathologic complete response is related to p53 overexpression. *Proc. ASCO* 2004;23:95,#880.
69. Dookeran KA, Sciupokiene E, Naujokas A, Wang Y, Lin JM, Ferrer K, Sekosan M, Zhang S, Gao X, Zaren HA. Improved yield of perioperative screening for metastases in African-American women with operable breast cancer. *Breast Cancer Research & Treatment* 2004;88:S97.
70. Dookeran KA, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Naujokas A, Sciupokiene E, Zaren HA. Analysis of hormone receptor function in African-American women with breast cancer. *Breast Cancer Research & Treatment* 2004;88:S98.
71. Dookeran KA, Ferrer K, Sekosan M, Gao X, Sciupokiene E, Wang Y, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Song S, Zaren HA. HER2/neu overexpression and survival in African-American women with breast cancer. *Proc. AACR* 2005;46:114-15,#489.
72. Dookeran KA, Sciupokiene E, Wang Y, Lin J, Naujokas A, Whitehall M, Muthyala N, Rogowski WA, Zaren HA. Health attitudes, beliefs and habits affect breast cancer screening practice among minority-underserved and low income women. *Proc. AACR* 2005;759:#3227
73. Dookeran KA, Ferrer K, Sekosan M, Sciupokiene E, Gao X, Wang Y, Lukaszczyk B, Diaz de Leon L, De La Torre R, Zaren HA. p53 expression predicts poorer survival in African-American women with breast cancer. *Proc. ASCO* 2005;23:870s,#9635.
74. Dookeran KA, Wang Y, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Roman G, Muthyala N, Rogowski WA, Zaren HA. Low socio-economic status African-American, Hispanic White women with breast cancer demonstrate similar hormone receptor status, tumor grade survival. *Breast Cancer Research & Treatment* 2005;94:S156.
75. Dookeran KA, Ferrer K, Sekosan M, Gao X, Wang Y, Diaz de Leon L, Lukaszczyk B, De La Torre R, Roman G, Radeke ER, Muthyala N, Rogowski WA, Zaren HA. Underserved African-American & white women with breast cancer have similar prognostic profiles for estrogen receptor and tumor grade. *Proc. AACR* 2006;47:#3696.
76. Dookeran KA, Ferrer K, Sekosan M, Gao X, Wang Y, De La Torre R, Lukaszczyk B, Diaz de Leon L, Roman G, Zaren HA. p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. *J. Clin. Oncol. Proc. ASCO* 2006;24:#10001.
77. Dookeran KA, Gao X, Wang Y, Ferrer K, Sekosan M, Lukaszczyk B, Roman G, De La Torre R, Jacobson A, Radeke ER, Mackevicius T, Zaren HA, McCaskill-Stevens W. p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer. *Proc. AACR* 2006:#A63.
78. Dookeran KA, Gao X, Wang Y, Lukaszczyk B, De La Torre R, Roman G, Ferrer K, Sekosan M, McCaskill-Stevens W, Zaren HA. p53 gene mutations in African-American women with breast cancer. *Breast Cancer Research & Treatment* 2006;100:S145.
79. Dookeran KA, Gao X, Wang Y, Ferrer K, Sekosan M, De La Torre R, Chang WJ, Khadir MM, Roman G, Lukaszczyk B, Radeke ER, McCaskill-Stevens W, Zaren HA. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. *Proc. AACR* 2007:#2510.
80. Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, De La Torre R, Radeke ER, McCaskill-Stevens W, Zaren HA. Absence of racial predilection for aggressive tumor phenotype among low socio-economic status women with breast cancer. *J. Clin. Oncol. Proc. ASCO* 2007;25:#10554.
81. Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Song S, Khadir M, Radeke ER, McCaskill-Stevens W, Zaren HA. Poverty predicts aggressive breast cancer phenotype and poor prognosis. *J. Clin. Oncol. Proc. ASCO 2007 Breast Cancer Symposium*:#138.
82. Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Song S, Lukaszczyk B, Chang WJ, Gonzalez E, Rogowski WA, Radeke ER, McCaskill-Stevens W, Zaren HA. Worsening degree of poverty predicts increased likelihood of ER/PR negative, triple negative & basal breast cancer subtypes. *Proc. AACR* 2008;49:#3838.
83. Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Lukaszczyk B, Radeke ER, McCaskill-Stevens W, Zaren HA, Gehlert S. p53 as an additional marker to the intrinsic subtype classification as a method to further stratify breast cancer survival in African American (AA) women. *Proc. ASCO* 2008;26:#22007.
84. Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Lukaszczyk B, Radeke ER, McCaskill-Stevens W, Zaren HA, Gehlert S. Further stratification of breast cancer survival in younger African American (AA) women using p53 as an additional marker to the intrinsic subtype classification. *J. Clin. Oncol. Proc. ASCO 2008 Breast Cancer Symposium*:#111.
85. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African-American (AA) women with breast cancer. *J. Clin. Oncol. Proc. ASCO* 2009;27:#22119.
86. Dookeran KA, Ferrer K, Sekosan M, McCaskill-Stevens W. Race-based survival and prognosis among lower SES women with ER/PR negative breast cancer. *Proc. AACR* 2010:#859.
87. Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, Radeke EK, Lad TE, Holloway N, McCaskill-Stevens W, Gehlert S. Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. *J. Clin. Oncol. Proc. ASCO* 2010;28:#10590.
88. Dookeran KA, Ferrer K, Sekosan M, Holloway N, McCaskill-Stevens W, Gehlert S. The influence of sociodemographic factors on breast cancer tumor biology. *J. Clin. Oncol. Proc. ASCO* 2011;29:#1553.

89. Dookeran KA, Rauscher GH, Silva A. Mammography history and the risk of mastectomy among women with breast cancer. Abstracts—45th Annual SER Meeting 2012: (http://www.epiresearch.org/meeting_12/abstracts-2012.pdf) #026-S.
90. Dookeran KA, Dabbous FM, Booth BJ. Race-based mortality as determined by intrinsic breast tumor subtype and p53 status. *J. Clin. Oncol. Proc. ASCO* 2013;31:#e12519.
91. Khan JY, Dookeran KA, Steinhorn RH, DeRegnier RA. Outcomes Following Implementation of 2010 CDC Chorioamnionitis Guidelines in Neonates. The 2013 Pediatric Academic Societies Meeting, Washington D.C. (http://www.abstracts2view.com/pasall/view.php?nu=PAS13L1_2922.328)
92. Dookeran KA, Silva A, Rauscher GH. Race/ethnicity and disparities in mastectomy use in the Breast Cancer Care in Chicago Study. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; *Cancer Epidemiol Biomarkers Prev* 2014;23(11 Suppl):Abstract nr B34. doi:10.1158/1538-7755.DISP13-B34.
93. Mahmoud AM, Macias V, Kresovich JK, Dookeran KA, Kajdacsy-Balla A, Wiley EL, Rauscher GH. Is p53 an independent marker of aggressiveness in an ethnically diverse sample of breast cancer patients, after accounting for molecular subtype? *Modern Pathology* 2014;27(S2):#255.
94. Dookeran KA, Mahmoud AM, Poulin M, Yan L, Ehrlich M, Kresovich JK, Macias V, Kajdacsy-Balla A, Wiley EL, Rauscher GH. Exploring the role of reproductive factors and DNA methylation in ethnic disparities in breast cancer tumor aggressiveness. In: Proceedings of the Seventh AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 9-12, 2014; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Epidemiol Biomarkers Prev* 2015;24(10 Suppl):Abstract nr B51.
95. Dookeran KA, Argos M, Kresovich JK, Rauscher GH. Characterization of *KCNK9* in *The Cancer Genome Atlas* breast cancer dataset. *J. Clin. Oncol. Proc. ASCO* 2015;33:#e1086 (suppl; abstr 1086, <http://meetinglibrary.asco.org/content/150470-156>)
96. Irizarry B, Dookeran KA, Rauscher GH. Exploring disparities in sentinel lymph node biopsy within the Breast Cancer Care in Chicago study. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; *Cancer Epidemiol Biomarkers Prev* 2016;25(3 Suppl):Abstract nr C31.
97. Dookeran KA, Kresovich JK, Argos M, Rauscher GH. The role of *KCNK9* and *TP53* on the racial disparity in biologically aggressive breast cancer subtype in *The Cancer Genome Atlas* (TCGA). In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; *Cancer Epidemiol Biomarkers Prev* 2016;25(3 Suppl):Abstract nr B49.
98. Shah M, Dookeran KA, Khan JY. Clinical outcomes associated with a failed infant car seat challenge. The 2016 Pediatric Academic Societies Meeting, Baltimore, MD. (IN PRINT)
99. Dookeran KA, Argos M. Two-pore domain potassium (K+) channel genes and triple-negative (TN) subtype in The Cancer Genome Atlas (TCGA) breast cancer dataset. In: Proceedings of the Ninth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sept 25-28, 2016; Fort Lauderdale, FL. AACR; *Cancer Epidemiol Biomarkers Prev* 2017;26(2 Suppl):Abstract nr B07. (http://cebp.aacrjournals.org/content/26/2_Supplement/B07)
100. Khan JY, Dookeran KA, Ritacco DG. Severity of disease accounts for early mortality difference between inborn and outborn infants treated with therapeutic hypothermia for neonatal encephalopathy. The 2017 Pediatric Academic Societies Meeting, San Francisco, CA. (IN PRINT)
101. Khan JY, Dookeran KA, Ritacco DG. Analysis of factors predictive of abnormal MRI in infants with hypoxic-ischemic encephalopathy treated with hypothermia. The 2017 Pediatric Academic Societies Meeting, San Francisco, CA. (IN PRINT)